Asia Pacific Veterinary Oncology Market Size & Outlook
Asia Pacific veterinary oncology market, 2018-2030 (US$M)
Related Markets
Asia Pacific veterinary oncology market highlights
- The Asia Pacific veterinary oncology market generated a revenue of USD 47.1 million in 2022.
- The market is expected to grow at a CAGR of 12.8% from 2023 to 2030.
- In terms of segment, chemotherapy was the largest revenue generating therapy in 2022.
- Immunotherapy is the most lucrative therapy segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2023 to 2030.
Asia Pacific data book summary
| Market revenue in 2022 | USD 47.1 million |
| Market revenue in 2030 | USD 123.7 million |
| Growth rate | 12.8% (CAGR from 2022 to 2030) |
| Largest segment | Chemotherapy |
| Fastest growing segment | Immunotherapy |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Surgery, Radiology, Chemotherapy, Immunotherapy |
| Key market players worldwide | Zoetis Inc Class A, Karyopharm Therapeutics Inc, Varian, Accuray Inc, PetCure Oncology, Boehringer Ingelheim, Elanco Animal Health Inc, One Health Group, Regeneus |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 20.3% of the global veterinary oncology market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- MEA is the fastest growing regional market and is projected to reach USD 16.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Veterinary Oncology Market Scope
Veterinary Oncology Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific veterinary oncology market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to veterinary oncology market will help companies and investors design strategic landscapes.
Chemotherapy was the largest segment with a revenue share of 28.03% in 2022. Horizon Databook has segmented the Asia Pacific veterinary oncology market based on surgery, radiology, chemotherapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
- Asia Pacific Veterinary Oncology Therapy Outlook (Revenue, USD Million, 2018-2030)
- Surgery
- Radiology
- Chemotherapy
- Immunotherapy
- Others
- Asia Pacific Veterinary Oncology Animal Type Outlook (Revenue, USD Million, 2018-2030)
- Canine
- Feline
- Asia Pacific Veterinary Oncology Cancer Type Outlook (Revenue, USD Million, 2018-2030)
- Lymphoma
- Mast cell cancer
- Mammary and Squamous cell cancer
- Others (Anal sac carcinoma)
Reasons to subscribe to Asia Pacific veterinary oncology market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific veterinary oncology market databook
-
Our clientele includes a mix of veterinary oncology market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific veterinary oncology market, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific veterinary oncology market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific veterinary oncology market
Asia Pacific Veterinary Oncology Market Share, 2022 & 2030 (US$M)
Asia Pacific veterinary oncology market
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
